PK-PD analysis
OtherThe danish medicines agency regards new knowledge in pharmacokinetics and pharmacodynamics as an intervention.
NCT Number: NCT00969891
The present study is not hypothesis driven but will explore the ability of pharmacokinetic-pharmacodynamic modelling to predict optimal dosage of the chemotherapeutic drugs used in therapy in adult patients with acute myeloid leukemia.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Rigshospitalet, Hematology clinic, Copenhagen, Denmark
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The danish medicines agency regards new knowledge in pharmacokinetics and pharmacodynamics as an intervention.
Time frame: after complete analysis of data
Time frame: within 3 months of sampling
Looking for future studies?
Notify MeMikkel Krogh-Madsen
Other
Population Based Pharmacokinetic and Pharmacodynamic Dosage Model for Cytarabine, Daunorubicin and Etoposide for Acute Myeloid Leukemia
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07295951
Acute Leukemias, Acute Lymphoblastic Leukemia
Manchester, United Kingdom
View Trial DetailsNCT05918692
Acute Myeloid Leukemia, Hematologic Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT06058741
Acute Myeloid Leukemia, Hematologic Diseases
Lecce, Apulia, Italy
View Trial DetailsNCT01541280
Acute Myeloid Leukemia, Bone Marrow Diseases
Nantes, France
View Trial Details